Navepdekinra

Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM) . Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis[1][2][3].

Product Specifications

CAS Number

[2467732-66-5]

Product Name Alternative

DC-806; LY4100504; S-011806

UNSPSC

12352005

Target

Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/navepdekinra.html

Purity

98.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=NN1CC)N[C@@H]([C@@]2([H])CC[C@@H](CC2)C)C(NC3=C(C=C(C=C3)[C@H](C)[C@@H](NC(CC)=O)C(N4CCN(CC4)C)=O)F)=O

Molecular Formula

C33H48FN7O4

Molecular Weight

625.78

References & Citations

[1]Paul R. Fatheree, et al. IL-17 Ligands And Uses Thereof. US20200247785A1.|[2]Kim D, et al. Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. Am J Clin Dermatol. 2025 May;26 (3) :307-320.|[3]Xiaobing Deng, et al. The Critical and Unexpected Role of a Methyl Group in Interleukin-17A Inhibitors. bioRxiv 2025.10.02.680113